62 reports

Tuberculosis, typhoid are examples of the bacterial diseases that are prevalent in many countries.

  • Musculoskeletal Disorder
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.

Top ## players hold majority of stake in the market ##.

  • Musculoskeletal Disorder
  • World
  • Market Size
  • Baxter International Inc.
  • Gilead Sciences, Inc.
  • ADVERSE EFFECTS OF THE DRUGS

You can easily book an appointment with one online.

  • Arthritis
  • Musculoskeletal Disorder
  • AbbVie Inc.
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd.

SR ONE ##.

  • Musculoskeletal Disorder
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group
  • CLASSIFICATION OF BIOLOGIC DMARDS FOR RHEUMATOID ARTHRITIS: BASED ON MECHANISM OF ACTION

AS PER THE FDA, THE SIDE EFFECTS ASSOCIATED WITH JAK INHIBITORS INCLUDE TUBERCULOSIS, INFECTIONS AND CERTAIN TYPES OF CANCERS.

  • Musculoskeletal Disorder
  • North America
  • United States
  • AbbVie Inc.
  • Astellas Pharma Inc.

Rheumatoid arthritis

4546 5000 3864
  • Epidemiology: Rheumatoid Arthritis in the US, Japan, and 5EU

There were no cases of tuberculosis, herpes zoster, opportunistic infection, or death (Keystone et al., 2015).

  • Musculoskeletal Disorder
  • Japan
  • United States
  • Pfizer Inc.
  • Roche Group

THERE WERE FOUR DEATHS; THREE IN THE ##MG GROUP DUE TO CARDIORESPIRATORY ARREST, UROSEPSIS WITH PULMONARY EMBOLISM (PE), AND DISSEMINATED TUBERCULOSIS; AND ONE IN THE ##MG GROUP (SUSPECTED PE).

  • Musculoskeletal Disorder
  • World
  • Demand
  • Forecast
  • Market Size

IT AFFECTS ## IN ##, ## TO ## IN ##, ## BIRTHS.

  • Clinical Trial
  • Hospital
  • Musculoskeletal Disorder
  • Nucleic Acid
  • GlobalData's company

## Alzheimer' s Disease ## Amyotrophic Lateral Sclerosis ## Chronic Renal Failure ## Coronary Artery Disease ## Depression ## Diabetic Retinopathy ## Duchenne Muscular Dystrophy ## Heart Failure ## Liver Fibrosis ##

  • Cancer
  • Mental Health
  • Musculoskeletal Disorder
  • Pathology
  • SomaLogic, Inc.
  • FEATURED NEWS & PRESS RELEASES
  • BARICITINIB - DRUG PROFILE

THERE WERE NO CASES OF TUBERCULOSIS OR GASTROINTESTINAL PERFORATIONS.

  • Lymphoma
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Incyte Corporation

Rising prevalence of tuberculosis in women is driving growth of tuberculosis diagnostics across the globe.

  • Breast Cancer
  • Musculoskeletal Disorder
  • North America
  • United States
  • Market Size

There were no cases of tuberculosis or gastrointestinal perforations.

  • Musculoskeletal Disorder
  • Neurological Disorder
  • United States
  • Product Initiative
  • Pfizer Inc.

Efficacy was maintained at ## year.

  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • Galapagos NV

For serious AEs the ER/ ##PY was ##. ##, and for serious infections it was ##. ##, with ## confirmed case of active tuberculosis.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Therapy
  • United States

The increase was due to growth in our tuberculosis and tick-borne disease businesses.

  • Clinical Trial
  • Musculoskeletal Disorder
  • Neurological Disorder
  • United States
  • Grifols, S.A.

For serious AEs the ER/ ##PY was ##. ##, and for serious infections it was ##. ##, with ## confirmed case of active tuberculosis.

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative

There was no opportunistic infection or tuberculosis through week ##.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Novartis AG
  • CLINICAL TRIAL PROFILE SNAPSHOTS

RHEUMATIC DISORDERS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* RHEUMATIC DISORDERS THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* Country Name Phase IV Phase III Phase II/ III Phase II Phase I/ II Phase I Phase ## Total United States ## ## ## ## ## ##

  • Musculoskeletal Disorder
  • Pain Relief
  • Therapy
  • World
  • Product Initiative
  • POST MENOPAUSAL OSTEOPOROSIS - PIPELINE BY JHL BIOTECH INC, H2 2018
  • POST MENOPAUSAL OSTEOPOROSIS - PIPELINE BY IPSEN SA, H2 2018

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative

FOR SERIOUS AES THE ER/ ##PY WAS ##. ##, AND FOR SERIOUS INFECTIONS IT WAS ##. ##, WITH ## CONFIRMED CASE OF ACTIVE TUBERCULOSIS.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Company Operations
  • Product Initiative
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • ABALOPARATIDE
  • POST MENOPAUSAL OSTEOPOROSIS - PIPELINE BY LUPIN LTD, H1 2018

It undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Amgen Inc.
  • POST MENOPAUSAL OSTEOPOROSIS - PIPELINE BY NIBEC
  • POST MENOPAUSAL OSTEOPOROSIS - PIPELINE BY LUPIN LTD

The company undertakes extensive research and development of pharmaceuticals for treatment of migraine, gastrointestinal, psoriasis, central nervous system, cardiovascular, tuberculosis, diabetes and inflammation.

  • Arthritis
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Amgen Inc.
  • JUL 19, 2018: PHASE IIA STUDY DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE FOR BIOTESTS MONOCLONAL ANTIBODY BT-063 FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
  • LATEST CLINICAL TRIALS NEWS ON SYSTEMIC LUPUS ERYTHEMATOSUS

There were no deaths, malignancies, major adverse cardiovascular events, tuberculosis, or serious herpes zoster infections.

  • Cell Therapy
  • Clinical Trial
  • Musculoskeletal Disorder
  • World
  • GlaxoSmithKline plc

There were no cases of opportunistic infection, tuberculosis, thromboembolism, or malignancy.

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative

Kineret (anakinra) is a recombinant protein drug that blocks the biological activity of IL-##a and IL -##b by binding to interleukin-## type ## receptor (IL-R ##), expressed in a variety of tissues and organs, and thereby blocking the interleukin-## (IL-##) sign

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Pfizer Inc.
  • MAR 13, 2017: BRISTOL-MYERS SQUIBB'S ORENCIA REJECTS FOR USE WITHIN NHS SCOTLAND

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ##, ##, ## and ## respectively.

  • Musculoskeletal Disorder
  • United States
  • World
  • Product Initiative
  • Bristol-Myers Squibb Company

HL-## IS AN INTERLEUKIN-## (IL-##) ALPHA AND BETA INHIBITOR.

  • Biotechnology
  • Hospital
  • Musculoskeletal Disorder
  • Therapy
  • Novartis AG

Other warnings and precautions for Taltz include pre-treatment evaluation for tuberculosis, hypersensitivity reactions, inflammatory bowel disease and immunizations.

  • Arthritis
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Novartis AG

The molecules developed by Companies in Pre- Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ##, ## and ## respectively.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Company Operations
  • Coherus BioSciences, Inc.